Hematologic Oncology

Faculty offer insights into the future of PV management as well as unmet needs.

NXC-201 has received orphan drug designation from the European Commission for use in patients with amyloid light-chain amyloidosis.

The phase 3 ENHANCE-3 study of magrolimab plus venetoclax/azacitidine vs venetoclax/azacitidine in select patients with AML has been terminated.

The expert panel explores belumosudil's role in treating chronic GVHD after multiple systemic therapy lines. They discuss the ROCKstar trial, highlighting its overall response rates and real-world experiences.

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the approval and real-world experiences of ibrutinib and ruxolitinib for chronic GVHD. The panel discusses the challenges and varying effectiveness observed in real-world usage, contrasting the experiences of the two drugs.

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Andrew Brunner, MD, presents the profile of a 72-year-old man with MDS and the panel offers their initial impressions on the case, focusing on the treatment decisions.

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

The combination of the first-in-class inhibitor enasidenib plus venetoclax has generated excitement targeting IDH2 mutations in relapsed/refractory AML.

Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.

Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.

Panelists evaluate PFS, OS, and the prognostic significance of negative MRD.

Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

The expert panel explores the approval of ruxolitinib for chronic GVHD based on the REACH3 trial. The panel highlights the trial’s outcomes, long-term follow-up data, and the evolving shift in clinical practices.

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD.

An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.

Minoo Battiwalla, MD, discusses findings from a study of outpatient care after CAR T-cell therapy in patients with hematologic malignancies.

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.